Back to Archived Journals » Journal of Receptor, Ligand and Channel Research » Volume 3

Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension

Authors Hoette S, O’Callaghan DS, Jardim C, Souza R

Published 23 November 2010 Volume 2010:3 Pages 113—121


Review by Single anonymous peer review

Peer reviewer comments 2

Susana Hoette1,2, Dermot S O’Callaghan2, Carlos Jardim1, Rogerio Souza1
1Pulmonary Circulation Unit, Pulmonary Department, Heart Institute, University of São Paulo Medical School, Sao Paulo, Brazil; 2Hôpital Antoine Béclère, Université Paris Sud, Orsay, France

Abstract: Pulmonary hypertension is characterized by an increase in mean pulmonary arterial pressure and right ventricular overload. Endothelin-1 (ET-1) is a potent vasoconstrictor with an important role in the pathogenesis of pulmonary hypertension. In addition to its vasoconstrictive action, ET-1 also stimulates cell proliferation, fibrosis, and inflammation. The blockade of both receptors involved in the action of ET-1 is beneficial in the treatment of pulmonary hypertension. The use of endothelin dual receptor blockade leads to improvements in quality of life, functional capacity, and pulmonary hemodynamics in affected patients. This article reviews the importance of ET-1 in the pathogenesis of pulmonary hypertension and demonstrates the benefits of blockage of the action of ET-1 in this disease.

Keywords: pulmonary hypertension treatment, endothelin-1, endothelin receptor blockage, bosentan

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]